Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$13000.0.

  • Sangamo Therapeutics' Capital Expenditures rose 7045.45% to -$13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$34000.0, marking a year-over-year decrease of 10111.11%. This contributed to the annual value of $267000.0 for FY2024, which is 9873.79% down from last year.
  • Per Sangamo Therapeutics' latest filing, its Capital Expenditures stood at -$13000.0 for Q3 2025, which was up 7045.45% from -$133000.0 recorded in Q2 2025.
  • In the past 5 years, Sangamo Therapeutics' Capital Expenditures registered a high of $10.2 million during Q1 2023, and its lowest value of -$133000.0 during Q2 2025.
  • In the last 5 years, Sangamo Therapeutics' Capital Expenditures had a median value of $2.8 million in 2022 and averaged $3.4 million.
  • Per our database at Business Quant, Sangamo Therapeutics' Capital Expenditures surged by 25928.14% in 2023 and then crashed by 39259.26% in 2025.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Capital Expenditures stood at $2.9 million in 2021, then skyrocketed by 161.51% to $7.5 million in 2022, then plummeted by 64.26% to $2.7 million in 2023, then tumbled by 104.57% to -$122000.0 in 2024, then surged by 89.34% to -$13000.0 in 2025.
  • Its Capital Expenditures stands at -$13000.0 for Q3 2025, versus -$133000.0 for Q2 2025 and $234000.0 for Q1 2025.